XML 67 R54.htm IDEA: XBRL DOCUMENT v3.20.2

Commitments - Additional Information (Details) - USD ($) $ in Thousands		1 Months Ended		3 Months Ended		9 Months Ended
	Dec. 02, 2020	Sep. 30, 2020	Aug. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Oct. 31, 2016
Loss Contingencies [Line Items]
Rent expense						$ 1,500	$ 1,600
Research and development				$ 2,706	$ 2,359	$ 7,713	7,966
Revenue Share Agreement | Oncimmune Limited
Loss Contingencies [Line Items]
Percentage of revenue share payment related to acquired diagnostic test recognized revenue for non-screening tests						8.00%
Minimum annual volume percentage thereafter						5.00%
Period of escalations of sales						through the first four years of sales
Revenue share expenses				0		$ 200
Bio-Rad License
Loss Contingencies [Line Items]
Percentage of royalty payments on net revenue			2.50%
License expiry date			2024-08
Royalty expense						100	0
AVEO Oncology
Loss Contingencies [Line Items]
Research and development				$ 300	$ 700	$ 1,000	$ 900
AVEO Oncology | Scenario
Loss Contingencies [Line Items]
Remaining estimated obligation	$ 300
AVEO Oncology | NSCLC POC Trial
Loss Contingencies [Line Items]
Responsible percentage of development and regulatory costs								50.00%
Ficlatuzumab | AVEO Oncology
Loss Contingencies [Line Items]
Percentage of development and regulatory costs exercised using opt-out right		50.00%
Ficlatuzumab | AVEO Oncology | Scenario
Loss Contingencies [Line Items]
Percentage of royalty payments on net sales	10.00%
Percentage of license income generated from licensing	25.00%
BDX004 | Ficlatuzumab | AVEO Oncology | POC Clinical Trials
Loss Contingencies [Line Items]
Responsible percentage of development and regulatory costs								50.00%

X

- Definition

License agreement expiry date.

+ References

No definition available.

+ Details

Name:	bdsx_LicenseAgreementExpiryDate
Namespace Prefix:	bdsx_
Data Type:	xbrli:gYearMonthItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Minimum annual volume percentage thereafter.

+ References

No definition available.

+ Details

Name:	bdsx_MinimumAnnualVolumePercentageThereafter
Namespace Prefix:	bdsx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percentage of development and regulatory costs.

+ References

No definition available.

+ Details

Name:	bdsx_PercentageOfDevelopmentAndRegulatoryCosts
Namespace Prefix:	bdsx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Percentage of development and regulatory costs exercised using opt-out right.

+ References

No definition available.

+ Details

Name:	bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight
Namespace Prefix:	bdsx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percentage of license income generated from licensing.

+ References

No definition available.

+ Details

Name:	bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing
Namespace Prefix:	bdsx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percentage of revenue share payment related to acquired diagnostic test recognized revenue for non-screening tests.

+ References

No definition available.

+ Details

Name:	bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests
Namespace Prefix:	bdsx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percentage of royalty payments on net revenue.

+ References

No definition available.

+ Details

Name:	bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue
Namespace Prefix:	bdsx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percentage of royalty payments on net sales.

+ References

No definition available.

+ Details

Name:	bdsx_PercentageOfRoyaltyPaymentsOnNetSales
Namespace Prefix:	bdsx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Period of escalations of sales.

+ References

No definition available.

+ Details

Name:	bdsx_PeriodOfEscalationsOfSales
Namespace Prefix:	bdsx_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Remaining estimated obligation.

+ References

No definition available.

+ Details

Name:	bdsx_RemainingEstimatedObligation
Namespace Prefix:	bdsx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Revenue share expenses.

+ References

No definition available.

+ Details

Name:	bdsx_RevenueShareExpenses
Namespace Prefix:	bdsx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41499-112717

+ Details

Name:	us-gaap_OperatingLeasesRentExpenseNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

Name:	us-gaap_RoyaltyExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=bdsx_RevenueShareAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=bdsx_OncimmuneLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_BioRadLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=bdsx_AVEOOncologyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_NSCLCPOCTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_EquitySecuritiesByIndustryAxis=bdsx_FiclatuzumabMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=bdsx_BDX004Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_POCClinicalTrialsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: